Craig C. Hopkinson Sells 144,419 Shares of Alkermes plc (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson sold 144,419 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now owns 57,875 shares of the company’s stock, valued at $2,056,298.75. This represents a 71.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Alkermes Stock Performance

NASDAQ:ALKS opened at $35.89 on Friday. The stock has a 50-day simple moving average of $30.40 and a two-hundred day simple moving average of $28.80. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.25. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The firm has a market capitalization of $5.81 billion, a PE ratio of 18.41, a P/E/G ratio of 1.83 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Analysts forecast that Alkermes plc will post 2.23 EPS for the current year.

Institutional Trading of Alkermes

Several hedge funds have recently bought and sold shares of the stock. CIBC Asset Management Inc grew its holdings in Alkermes by 4.4% during the fourth quarter. CIBC Asset Management Inc now owns 9,155 shares of the company’s stock valued at $263,000 after purchasing an additional 384 shares during the period. O Shaughnessy Asset Management LLC lifted its position in shares of Alkermes by 3.9% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 14,203 shares of the company’s stock valued at $408,000 after acquiring an additional 532 shares in the last quarter. Nicollet Investment Management Inc. lifted its position in shares of Alkermes by 1.7% in the third quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock valued at $1,227,000 after acquiring an additional 714 shares in the last quarter. KBC Group NV lifted its position in shares of Alkermes by 18.8% in the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after acquiring an additional 774 shares in the last quarter. Finally, Sei Investments Co. lifted its position in shares of Alkermes by 1.1% in the fourth quarter. Sei Investments Co. now owns 75,394 shares of the company’s stock valued at $2,168,000 after acquiring an additional 828 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

Wall Street Analysts Forecast Growth

ALKS has been the subject of several recent analyst reports. Cantor Fitzgerald decreased their price target on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Deutsche Bank Aktiengesellschaft initiated coverage on Alkermes in a research note on Tuesday, February 11th. They issued a “buy” rating and a $40.00 price target for the company. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and boosted their price target for the stock from $25.00 to $36.00 in a research note on Tuesday, November 5th. JPMorgan Chase & Co. decreased their price target on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Mizuho boosted their price target on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and an average target price of $37.25.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.